UNICREDIT BANK/CALL/NOVO-NORDISK B/600/0.2/18.12.24 | Real-time BOERSE MUENCHEN 09:46:08 2024-07-17 am EDT | ||
| 9.08 EUR | -8.84% |
|
| Current month | -8.62% | ||
| 1 month | -7.69% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 24-07-17 | 9.08 | -8.84% |
| 24-07-16 | 9.96 | -1.09% |
| 24-07-15 | 10.07 | -1.66% |
| 24-07-12 | 10.24 | +4.17% |
| 24-07-11 | 9.83 | -5.12% |
Real-time BOERSE MUENCHEN
Last update July 17, 2024 at 09:46 am EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
UniCredit
|
| WKN | HC7P39 |
| ISIN | DE000HC7P391 |
| Date issued | 2023-06-26 |
| Strike | 600 kr |
| Maturity | 2024-12-18 (154 Days) |
| Parity | 5 : 1 |
| Emission price | 1.73 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 11.65 € |
|---|---|
| Lowest since issue | 1.3 € |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
970
DKK
Average target price
956.8
DKK
Spread / Average Target
-1.36%
- Stock Market
- Warrants
- Warrant
